Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 10:14:1-11.
doi: 10.2147/BTT.S236433. eCollection 2020.

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Eman Al Sulais  1 , Turki AlAmeel  2
Affiliations
Review

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Eman Al Sulais et al. Biologics. .

Abstract

Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.

Keywords: biosimilars; inflammatory bowel disease; tumor necrosis factor inhibitors.

PubMed Disclaimer

Conflict of interest statement

ES declares no conflicts of interest related to this study. TA has received consulting and speaker fees from Janssen, AbbVie, and Takeda.

Figures

Figure 1
Figure 1
An approach to introducing a biosimilar to inflammatory bowel disease (IBD) practice. Abbreviation: PK/PD, pharmacokinetic/pharmacodynamic.
See this image and copyright information in PMC

References

    1. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770. doi: 10.1016/S0140-6736(16)32126-2 - DOI - PMC - PubMed
    1. Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755. doi: 10.1016/S0140-6736(16)31711-1 - DOI - PubMed
    1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913. doi: 10.1053/j.gastro.2008.09.012 - DOI - PMC - PubMed
    1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035. doi: 10.1056/NEJM199710093371502 - DOI - PubMed
    1. Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. doi: 10.1136/bmj.j2505 - DOI - PubMed